Texas Keeps Rewriting Its Ketamine Rules. Here Is What Changed and What It Means for Your Clinic
The Texas Medical Board was expected to vote on its sweeping ketamine regulations in June. That vote never came. Instead, the board withdrew its original proposal, published a revised version in the May 15 Texas Register, and has now revised the rules again. The latest proposal published in the July 10 Texas Register, restarting the rulemaking process once more and opening a fresh public comment window that is live right now. Most Texas clinic owners have no idea any of this happened. They should. The revisions reveal exactly where the board is willing to bend, and where it is not.
Do you run a ketamine clinic? HealingMaps has launched the first Group Purchasing Organization built for the ketamine industry — and it’s free to join. Members get 40%+ off medical supplies, discounted professional liability and medmal insurance for ketamine practitioners, LegitScript certification at a reduced rate, and HIPAA-compliant credit card processing. There’s zero cost or obligation to become a member.
→ healinghealthalliance.com/contact
| Key Takeaway | Detail |
|---|---|
| The June vote did not happen | The board withdrew the January proposal, revised it on May 15, and revised it again; the latest version published in the July 10 Texas Register |
| The onsite physician mandate softened | The July text keeps the remote supervision model and raises the cap: midlevel providers can treat up to three patients without a physician on site, RNs one |
| The home use ban survived | Administering or prescribing parenteral ketamine for home use remains prohibited |
| Monitoring rules expanded | The May revision grew from ten sections to thirteen; the July version consolidates to twelve and adds emergency response and adverse event reporting requirements |
| The comment window is open now | Clinics can submit feedback through the board’s online comment form or by email; a public hearing will follow at a date not yet announced |
| Sublingual telehealth remains outside scope | The rules cover only IV, IM, and subcutaneous routes |
What Actually Happened in May
The original rules, published January 2 as Chapter 173, Subchapter B, drew heavy fire during the first comment period. The loudest objection targeted one provision. The January draft required a delegating physician to be immediately available on site throughout every ketamine session. Clinic owners argued the mandate would force closures across the state. Many practices run on a model where nurse practitioners or CRNAs administer infusions while the physician supervises remotely.
The board listened, at least partially. Rather than adopt the rules as written, it withdrew them and published a revised proposal covering sections 173.6 through 173.18. Under the board’s own rulemaking process, republication resets everything. The new version gets its own comment period and its own public hearing before any adoption vote.
That process has now repeated itself. The further revised proposal, covering sections 173.6 through 173.17, published in the July 10 Texas Register. The May version ran through 173.18. The July text consolidates rather than cuts. The hospice exception lost its standalone section and now sits inside a broader registration exemptions provision, and a new section on emergency response and adverse event reporting appeared. Each republication restarts the clock.
The Two Patient Compromise
The biggest change in the May revision addressed the staffing question directly. Under that version, medical staff can administer ketamine without a physician on site, but only to two patients at a time. Cross that threshold and a physician must be physically present.
Ask yourself what this means for your schedule. Under the July ratios, a clinic running six simultaneous infusions under one remote physician needs two midlevel providers on the floor, since each tops out at three patients without a physician on site. An RN working alone covers a single patient. For high volume infusion practices, that math changes everything. Revenue per hour drops sharply unless physician staffing expands. For smaller practices already running one or two patients at a time, the revised rule is survivable in a way the January version was not.
The revised rules also require providers to complete training on mental health treatment before administering ketamine. Document that training now. The board has signaled it will expect proof.
The July text answers the question clinics have been asking since May, and the news is mostly good. The allowance survived and got more generous for midlevel providers, who can now manage up to three patients at a time without a physician on site. RNs working alone are capped at one patient. When a physician is physically present, the ceilings rise to four patients per midlevel provider and two per RN. The board also wrote a post treatment ratio into the rules: one monitoring delegate for every four patients.
What the Board Refused to Change
The retreat on physician presence should not be mistaken for a broader softening. The core architecture of the January proposal survived the May revision intact.
The home use ban stands. Section 173.15 of the revised rules prohibits administering ketamine outside a registered clinic or exempt setting. It also prohibits prescribing parenteral ketamine for home use. Any practice sending patients home with injectable ketamine must end that program if these rules pass.
Mandatory registration stands. Every practice providing psychotropic ketamine therapy must register with the board, with limited exemptions for hospitals, medical schools, and licensed hospice programs. Registration runs two years and lapses if renewal paperwork misses the 60 day deadline. A lapsed registration means a mandatory shutdown until renewal clears.
The enforcement framework stands. Registered clinics face audits, inspections, and investigations under the same rules that govern pain management clinics. Medical directors and physician owners carry personal responsibility for compliance. A staffing violation is not a clinic problem. It is a license problem.
The Monitoring Rules Got Longer, Not Shorter
The May revision grew the proposal from ten sections to thirteen, largely by splitting monitoring into distinct phases. The July text consolidates to twelve sections but keeps that structure. Section 173.12 governs monitoring after the infusion ends and before the patient leaves, section 173.13 sets minimum equipment and medication requirements, and a new section 173.14 adds emergency response and adverse event reporting obligations.
This matters for your discharge workflow. Clinics that walk patients to the lobby fifteen minutes after an infusion should review their protocols now. The board is writing post treatment observation into regulation, with equipment standards drawn from office based anesthesia settings. Budget for monitoring equipment if your treatment rooms lack it.
What Remains Outside the Rules
The scope did not expand. These rules govern parenteral ketamine only, meaning IV, intramuscular, and subcutaneous routes. Sublingual lozenges and oral formulations prescribed through telehealth sit entirely outside this framework.
That gap is worth watching. Board representatives have publicly criticized at home telehealth ketamine as a safety concern, yet the current proposal does not touch it. State authority over out of state telehealth prescribers is limited. The federal government controls that lane, and the DEA telehealth flexibilities that make the at home model possible expire December 31. We covered that deadline in depth in our breakdown of the DEA telehealth cliff.
What These Rules Mean for Your Clinic
Strip away the procedural back and forth and the July proposal comes down to eight operational changes. Here is what your clinic will need to do if the rules pass as written.
| Requirement | What Your Clinic Must Do |
|---|---|
| Mandatory registration (173.7) | Register with the board before providing psychotropic ketamine therapy. Registration renews every two years, and missing the 60 day renewal deadline means shutting down until renewal clears. |
| Staffing ratios without a physician on site | Cap concurrent patients at three per midlevel provider and one per RN, or put a physician in the building to raise the ceilings to four and two. |
| Post treatment monitoring (173.12) | Keep patients under formal observation after the infusion ends, with at least one monitoring delegate for every four patients. Update your discharge protocol to document it. |
| Equipment and medication standards (173.13) | Outfit treatment rooms with monitoring equipment and medications drawn from office based anesthesia standards. Budget for purchases if your rooms fall short. |
| Emergency response and adverse event reporting (173.14) | Put emergency response procedures in place and be prepared to report adverse events to the board. |
| Home use ban (173.15) | End any program that sends patients home with injectable ketamine. Sublingual and oral telehealth prescribing sits outside these rules. |
| Provider training | Complete and document training on mental health treatment before administering ketamine. The board will expect proof. |
| Audits and inspections (173.17) | Keep records inspection ready. Registered clinics face the same audit framework as pain management clinics, and the medical director carries personal responsibility for violations. |
What Texas Clinics Should Do This Week
Read the July text now. Compare it against your current staffing model, your discharge protocol, and your equipment list, and start by spotting what changed from the May version.
Then comment. The board already proved it responds to industry feedback. The two patient allowance exists because clinic owners spoke up during the first window. The comment window opened with the July 10 publication and is your next chance to shape provisions that remain unworkable, and possibly your last. Comments can be submitted through the board’s online comment form or by email to the board’s rules development address, both listed in the Register notice. Texas requires the window to stay open at least 30 days from publication, so plan to file by early August. A public hearing will follow at a date the board has not yet announced.
Finally, plan for adoption. Some version of these rules is coming. The board withdrew and rewrote rather than abandoning the effort, which signals commitment, not retreat. Clinics that begin restructuring now will absorb the transition. Clinics that wait for the adoption vote will scramble.
Texas Will Not Be the Last
State medical boards across the country are watching this process closely. Texas is the second most populous state, and its regulatory frameworks travel. Health law firms are already advising clients in other states to treat the Texas rules as a preview of their own future requirements. In the coming weeks we will map which states show the strongest signals of following, and what clinic owners in those markets should prepare for now.
